Abstract. Retinoid X receptor-· (RXR·) fragments are known to be produced in some cancer cells by proteolytic cleavage. Previous finding that ligand binding domain (LBD) fragment of RXR· specifically inhibits retinoic acid receptor-Á (RARÁ) activity led us to investigate the functional role of RXR· LBD fragment in radiosensitization by retinoic acid (RA). Ectopic expression of RXR· LBD fragment in cells that do not have a detectable endogenous RXR· LBD fragment, blocked synergistic radiosensitizing action of RA, as determined by growth inhibition, cell death and colony formation assays. However, H460 cell, which has an endogenous RXR· LBD fragment, was not radiosensitized by RA regardless of the ectopic RXR· LBD fragment expression. These results were paralleled with the pattern of p21 induction by the treatment of RA in combination with ionizing radiation (IR). Taken together, we hypothesize that the RXR· LBD fragment may act as a negative regulator of radiosensitizing effect of RA by restricting the RARÁ-mediated biological response to RA.
Introduction
All-trans retinoic acid (RA), the major physiologically active form of vitamin A metabolites, exerts profound effects on many biological processes, including cell proliferation, differentiation and morphogenesis (1) . The pleiotropic effects of RA are mediated by the retinoic acid receptors (RARs) and their heterodimerization partners, the retinoid X receptors (RXRs) (2, 3) . RARs consist of 3 subtypes, ·, ß and Á. Some extent of functional redundancy among three subtypes of RARs in retinoid signaling has been demonstrated in various context (3) (4) (5) . However, many lines of evidence indicate that each subtype of RARs plays a distinct role in a variety of biological processes (6) . RARÁ was reported to be the main mediator for the RA-induced growth inhibition and apoptosis in keratinocytes (7, 8) , and for the regulation of the balance between hematopoietic stem cell self-renewal and differentiation (9) .
In a recent study, we have demonstrated that RARÁ is distinguished from other RAR subtypes by its unique cytoplasmic localization, which is regulated by complex interactions among ligand binding, phosphorylation, and receptor dimerization (10) . We also explored a novel function of the ligand binding domain (LBD) fragment of RXR· as a specific negative regulator of RARÁ. The RXR· LBD fragment inhibits nuclear translocation, receptor dimerization and consequently the transcriptional activity of RARÁ in a very specific manner without affecting those of RAR· and -ß subtypes. In relation to this observation, it is worth noting that RXR· can actually be cleaved in vivo to produce a fragment of similar size to LBD fragment of RXR·. Two research groups have previously reported that they detected proteolytic activity to cleave RXR· at near N-terminus yielding C-terminal fragments of several sizes and characterized the responsible proteases as cathepsin L-type protease and m-calpain, respectively (11) (12) (13) . One of the groups suggested that cytosolic cathepsin L-type protease activity might modulate thyroid hormone receptor activity by regulating the turnover of its heterodimerization partner, RXR· (11) .
Several studies have demonstrated sensitizing effect of retinoids to ionizing radiation (IR) in various tumors (14) (15) (16) (17) . Radiosensitization is one of the many important cellular responses to RA. The mechanism of radiosensitization by retinoids is not fully understood, although some suggestions have been reported (18, 19) . Thus, it is of interest to investigate the function of RXR· LBD fragment in the radiosensitization by RA in cancer cells. We report that RXR· LBD fragment completely blocks radiosensitizing action of RA, highlighting the importance of RARÁ in the radiosensitizing process induced by RA and suggesting the possibility that the presence of RXR· LBD fragment may serve as a determinant for the susceptibility to radiosensitization by RA.
Materials and methods
Cell culture and plasmid constructs. SiHa cells were grown in minimal essential medium, H460, A549 and H1299 were grown in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS). Retroviral vector for RXR· mutant expression was prepared as following. The cDNA covering amino acids 222-462 of RXR· was amplified by polymerase chain reaction with an addition of start codon at the Nterminus, and inserted into the cloning site of a retroviral vector MFG-puro in a right orientation.
Establishment of stable cell lines.
Retroviruses were prepared by introducing MFG construct into retrovirus packaging cell line, H29D, by transient transfection using lipofectamine 2000 (Invitrogen). After 72 h, the supernatants containing viruses were harvested and filtered through 0.2 μM pores after addition of Polybrene (6 μg/ml). Target cell lines were infected with the viruses titered between 10 5 and 5x10 5 /ml and selected for 3 days in growth medium containing puromycin at 2 μg/ml.
Western blotting. Cell lysates were boiled in sodium dodecyl sulfate (SDS) sample buffer, resolved by SDS-polyacrylamide gel electrophoresis (8 or 12.5% polyacrylamide), and transferred to nitrocellulose. After transfer, the membranes were blocked in 5% milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween-20) for 30 min and incubated with primary antibody in 5% milk in TBST for 2 h at room temperature. The membranes were washed three times with TBST, and incubated for 1 h at room temperature in TBST containing horseradish peroxidase-linked antimouse or rabbit immunoglobulin (Santa Cruz). After triple washes in TBST, immunoreactive products were detected by chemiluminescence with an enhanced chemiluminescence system (ECL, Amersham).
Growth inhibition. Cells were seeded in 96-well plates and allowed to attach for 24 h, and then treated with all-transretinoic acid (RA) at 1 μM for 12 h or not. Cells were then irradiated or not and allowed to grow for 72 h. The number of viable cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay (Cell Titer 96 AQueous Non-radioactive Cell Proliferation Assay, Promega, Madison, WI) according to the manufacturer's protocol. Three replicates were done for each treatment.
Colony-formation assay. Clonogenic cell survival was evaluated by colony-forming assay. Cells were seeded at a density of 200 cells/60 mm dish a day before the treatment of RA (1 μM). Cells were then irradiated at the indicated doses 12 h after RA treatment. After 2 weeks of incubation, cells were fixed with 3.7% formaldehyde and stained with crystal violet. Colonies larger than 0.6 mm in diameter were counted. Three replicates were done for each treatment.
Cell death analysis. Apoptotic cell death was determined by Annexin V-FITC/propidium iodide double staining using Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences) according to the manufacturer's recommendation. The cells were then analyzed using a FACScan flow cytometer (BD Biosciences).
Irradiation of cells. Cells were plated in 3.5-cm dishes and incubated at 37˚C under humidified 5% CO 2 -95% air in culture medium until cells reached 70-80% confluent. Cells were then exposed to Á-rays with 137 Cs Á-ray source (Atomic Energy of Canada, Ltd., Canada) with a dose rate of 3.81 Gy/min.
Results

Endogenous 30 kDa LBD fragment of RXR· is present in some cell lines.
In a previous report, we demonstrated that Cterminal 30 kDa LBD fragment of RXR· plays a unique role in the regulation of subcellular localization and transcriptional activity of RARÁ (10). Since there have been several reports describing the generation of truncated RXR· C-terminal fragment by proteolytic cleavage in cancer cells (11) (12) (13) , we wanted to check whether RXR· C-terminal fragment of a similar size was endogenously produced in various cancer cell lines. Using the antibody specific to the C-terminal region of RXR·, we could detect C-terminal fragment of RXR· at about 30 kDa in certain cells such as H460 lung cancer cells, and HepG2 hepatocarcinoma cells, while there was no detectable level of this RXR· fragment in other cell lines tested (Fig. 1A) .
LBD fragment of RXR· blocks the synergistic action of RA on IR-induced growth inhibition.
To examine the function of RXR· LBD fragment, we first tried to establish stable cell lines that express the RXR· LBD fragment (RXR-F) using retroviral expression system and puromycin selection. For this purpose, we constructed retroviral vector designed to express RXR· fragment of 222-462 amino acid residues, which has been shown to specifically inhibit the nuclear translocation and transcriptional activity of RARÁ (10) . Three cell lines that do not have detectable endogenous RXR· LBD fragment (SiHa, A549 and H1299) in addition to one that have endogenous RXR· LBD fragment (H460) were chosen to establish stable cell lines, and they were confirmed to express RXR-F stably (Fig. 1B) .
Firstly, we carried out MTS cell proliferation assay using the established stable cell lines to assess the effect of RXR-F expression on the synergistic action of RA on the growth inhibition by IR (Fig. 1C) . As expected, IR inhibited cell growth of all four cell lines tested dose-dependently ONCOLOGY REPORTS 23: 1715-1720, 2010 Figure 2 . LBD fragment of RXR· blocks radiosensitizing effect of RA in colony formation assay. Indicated stable cell lines were seeded (300 cells in 60-mm dishes) and irradiated at the indicated dose after pretreatment of RA at 1 μM for 12 h or not. After 10-14 days of incubation, the colonies larger than 0.6 mm in diameter were counted. Experiments were done in triplicates.
regardless of the RXR-F expression. Pretreatment of RA significantly enhanced the growth-inhibitory effect of IR in control cell lines of SiHa, A549 and H1299, which lack endogenous RXR· LBD fragment. When RXR-F was expressed in these cell lines, however, the synergistic effect of RA on the IR-induced growth inhibition was completely blocked. In contrast, RA pretreatment did not cause further growthinhibition after IR treatment in H460 that have endogenous RXR· LBD fragment, regardless of ectopic expression of RXR-F.
LBD fragment of RXR· blocks the sensitizing effect of RA on clonogenic survival after IR.
We next performed colonyformation assay to evaluate the effect of RXR· LBD fragment on RA-mediated sensitization in clonogenic survival after IR (Fig. 2) . Control or RXR-F expressing stable cells were irradiated with or without the pretreatment of RA. The number of colonies formed after a period of incubation decreased as IR dose was increased. The number of surviving colony was decreased more when RA was pretreated before irradiation in SiHa, A549 and H1299 cells. Ectopic expression of RXR-F largely abolished this sensitizing effect of RA ( Fig. 2A-C) . However, RA pretreatment did not result in sensitization of H460 cells to IR, regardless of ectopic expression of RXR-F (Fig. 2D ). These observations are very similar to the case of growth inhibition assay in Fig. 1C .
LBD fragment of RXR· blocks enhancement of IR-induced cell death by RA.
We recognized from the above growth inhibition and colony formation assay that RA could sensitize cells without endogenous RXR· LBD fragment to IR, and ectopic RXR-F could block the RA effect. To further support these observations, we chose H460 and SiHa as representative of the with or without endogenous RXR· LBD fragment, respectively, to analyze RA effect on IR-induced cell death. Cells were stained with Annexin-V/PI and analyzed using FACS after combined treatment of RA and IR in the presence or absence of ectopic RXR-F expression. As shown in Fig. 3A , pretreatment of RA caused significant reduction of the percentage of live cells after irradiation in SiHa cell in the absence of RXR-F expression. RXR-F expression blocked again this sensitizing effect of RA. On the other hand, RA pretreatment did not cause increase of cell death after irradiation in H460 (Fig.  3B) . Ectopic expression of RXR-F in H460 did not make any difference to the RA effect on IR-induced cell death, but rendered the cells more sensitive to some extent to IR regardless of RA pretreatment.
LBD fragment of RXR· inhibits p21
Waf1/Cip1 induction by RA. We next wanted to examine whether RXR· LBD fragment can modulate the molecular response of cells to IR in combination with RA. Since cyclin-dependent kinase inhibitor, p21
Waf1/Cip1 , a well known effector protein for DNA damage response, is known to be induced by both IR and RA (20-22) , we decided to determine the expression level of p21
Waf1/Cip1 after single or combined treatment of IR and RA. In SiHa control cells, treatment of RA or IR increased the expression of p21
Waf1/Cip1 , and combined treatment of both resulted in the further synergistic increase of p21 Waf1/Cip1 (Fig. 4A) . However, RA treatment did not increase p21
Waf1/Cip1 expression regardless of co-treatment of IR in SiHa cell expressing RXR-F, while p21 Waf1/Cip1 induction by IR was intact in these cells. This suggests that RXR-F expression abrogated specifically RA-mediated induction of p21 Waf1/Cip1 through specific inhibition of RARÁ activity, while leaving the machinery for p21
Waf1/Cip1 induction by other kinds of stimuli intact. In H460 cells, on the other hand, RA treatment did not cause significant change in p21
Waf1/Cip1 expression from basal or IR-induced level no matter whether RXR-F was ectopically expressed or not (Fig. 4B ). IR alone was still able to induce p21
Waf1/Cip1 significantly in this cell type, regardless of ectopic expression of RXR-F. It is therefore possible that the endogenous 30 kDa C-terminal fragment of RXR· may contribute, to some extent, to the lack of p21 Waf1/Cip1 induction by RA in H460.
Discussion
Based on the previous findings that RXR· LBD fragment specifically inhibits RARÁ activity and LBD fragment of RXR· is produced in cells by proteolytic cleavage, we aimed to evaluate the functional role of RXR· LBD fragment in radiosensitization by RA. In the cells without endogenous RXR· LBD fragment used in this study, RA worked very well to enhance the response to IR at both cellular and molecular level, and ectopic expression of RXR· LBD fragment in these cells blocked the sensitizing effect of RA. Interestingly, H460 cells, in which endogenous RXR· LBD fragment was detected, did not respond to RA in terms of enhancing IR-induced cellular and molecular response. Since p21 Waf1/Cip1 is known to be induced by both IR and RA (20) (21) (22) , we chose p21
Waf1/Cip1 as an example among known RA-responsive genes to verify the effect of RXR· LBD fragment on the synergistic induction of downstream target gene by RA in combination with IR. Blocking of RAmediated induction of p21 Waf1/Cip1 by ectopic expression of RXR· LBD fragment clearly confirms that the actions of the RXR· LBD fragment on RARÁ at multiple levels demonstrated in previous study (10) actually operate in concert to repress the induction of endogenous target genes. It has been generally accepted that anti-cancer effects of retinoids are mediated by RARß, and the sensitivity to retinoid is directly correlated to the induction of RARß (23) (24) (25) . As to radiosensitization, however, the contribution of RARß is controversial (18, 26) . On the other hand, our results, which demonstrated the decisive role of RXR· LBD fragment in preventing the effect of RA enhancing IR-induced responses at both cellular and molecular level, propose RARÁ as a main player in radiosensitization by RA, since RXR· LBD fragment has been clearly shown to inhibit specifically RARÁ (10) .
There have been reports that C-terminal fragment of RXR· similar in size to LBD fragment is produced by proteolytic cleavage (11) (12) (13) . However, the biological significance of the fragmentation of RXR· was not fully addressed. One suggestion was that cathepsin L-type protease might regulate the response to thyroid hormone by modulating thyroid hormone receptor activity through the regulation of the turnover of its heterodimerization partner, RXR· (11) . The work was focused on the regulation of RXR· protein level by proteolytic cleavage, but not on RXR· cleavage product itself, thus presenting neither evidence nor insight into the possible functions of the RXR· cleavage product. Our results demonstrating the active role of RXR· LBD fragment in the regulation of RA-mediated radiosensitization provide new insight into the biological significance of proteolytic cleavage of RXR·. Thus, proteolytic cleavage of RXR· can be regarded as the cellular process not only to regulate RXR· protein level, but also to generate the active specific negative regulator of the biological processes in which RARÁ is involved. Since increasing evidence reveals that RARÁ is a critical regulator in more biological processes than expected, further study aimed to exploit the property of RXR· LBD fragment could provide the means to control various biological processes.
More systematic analysis using larger pool of cell lines or patient specimen might be required to derive a firm conclusion as to the direct correlation between the presence of endogenous RXR· LBD fragment and the loss of radiosensitization by RA. Nevertheless, our results suggest the possibility that the presence of RXR· LBD fragment may serve as a determinant for the susceptibility of cancer cells to radiosensitization by RA (Fig. 4C) , which can be exploited to develop a prognostic system for the combination radiotherapy with RA.
